Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Post by Francine01on Jun 29, 2020 4:59pm
181 Views
Post# 31205028

Incorrect design trial

Incorrect design trialMore I think about this call, more I think they incorrectly design the trial and won't ever admit, Jan need to be replaced. 

Its impossible that they can't control a placebo arm. If its the case, other trials would have fail and no investor would invest in a R&D if they can't control the placebo arm. 

Basically, the trial was incorrectly design, patients should not have been put on a severe diet during randomization, because it reduce significantly the TG, this is not rocket science.

Also, how could patients would be >500 mg/dl between randomization and under <500 mg/dl at week 0 and still be accepted as part of the research, it was designed for a fail. 

Are only hope is that T2 has not the same effect.

Management should leave. 

The conclusion, is that drug work, but trial incorrectly managed by incompetents  
Bullboard Posts